Nuwellis, Inc. (NUWE) is a medical technology company specializing in the development and commercialization of innovative fluid management solutions and services. Nuwellis, previously known as CHF Solutions, Inc, is headquartered in the United States and was incorporated in 1999. The company offers products primarily for treating fluid overload, typically caused by health conditions such as heart failure and critical care conditions. By focusing on fluid overload, the company addresses a significant unmet medical need in the most efficient, patient-centric manner.
The company's flagship product, Aquadex SmartFlow, stands at the core of its offering. This system provides an ultrafiltration process for the removal of salt and water in patients who fail to respond adequately to diuretic treatment. By applying this high-precision fluid management technology, it helps to remove excess fluid from the body, providing patients with a more comfortable experience and potentially reducing their time spent in the hospital.
In addition to the Aquadex system, Nuwellis provides comprehensive therapy implementation and clinical education services. The company’s medical, sales, and marketing teams work continuously to educate clinicians and healthcare professionals about the advantages of the Aquadex system, offering support for hospitals and clinics to implement this versatile therapy successfully.
Nuwellis Inc’s commitment to innovation and patient care has placed it as a leader in fluid management. The company has distinguished itself with its dedication to providing significant potential clinical benefits to patients with fluid overload, primarily caused by heart failure and other critical illnesses such as acute decompensated heart failure.
Nuwellis has expressed its vision to make a meaningful difference in the lives of patients suffering from fluid overload and improve healthcare services around the world. To achieve this, the company is continuously striving to make improvements in fluid management while prioritizing safety and patient comfort. This, in combination with the company's comprehensive support services, creates a strong value proposition for the healthcare industry.
In conclusion, Nuwellis Inc continues its commitment to medical technology innovation, coupled with high levels of service and support. The focus of the company on patient well-being and efficient, effective therapy has helped it to position as a strong emerging player in the field of fluid management. Whether it's through its revolutionary Aquadex system, active education programs, or dedicated customer support, Nuwellis Inc is uniquely positioned to make an impact on patient health and improve the treatment of fluid overload.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Nuwellis Inc. (NUWE) shares surged by 19.26% due to pivotal clinical progress aimed at pediatric growth. The company is establishing a Pediatric Medical & Nursing Advisory Board and pursuing a label expansion for its Aquadex SmartFlow system to include patients as small as 5 kg, down from the current 20 kg. Nuwellis is also aggressively showcasing Aquadex SmartFlow at four October medical conferences to deepen clinician engagement.
Nuwellis, Inc. announced the publication of results from the multicenter ULTRA-Peds Registry study in Pediatric Nephrology, supporting the use of its Aquadex SmartFlow® System for ultrafiltration in pediatric patients, including infants weighing less than 10 kg. The study, which evaluated 91 pediatric patients across seven children's hospitals, demonstrated high patient survival and procedure completion rates, providing crucial evidence for the proposed expansion of Aquadex's indication to patients weighing 5 kg and above. Nuwellis recently completed a pre-submission meeting with the FDA for this label expansion.
Nuwellis, Inc. announced the publication of a multicenter study, "Kidney Support in Infants and Children using Aquadex: Findings from the ULTRA-Peds Registry," in Pediatric Nephrology. The study evaluated 91 pediatric patients, demonstrating the Aquadex SmartFlow® System's effectiveness in kidney support and fluid management, particularly for those weighing less than 10 kg. These findings will support Nuwellis's proposed FDA label expansion of Aquadex’s indication to patients weighing 5 kg and above.
Nuwellis announced the publication of a multicenter study in Pediatric Nephrology, evaluating its Aquadex kidney support system in 91 pediatric patients. The study found that 87% of patients survived their treatment course, with 86.5% of procedures completed without interruption. These findings support Nuwellis's efforts to expand the Aquadex system's FDA-cleared labeling to include patients weighing 5 kg and above, down from the current 20 kg minimum.
Nuwellis Inc. has appointed Dale Brady as Principal R&D Engineer to advance its existing and new product development programs. Brady brings over 25 years of medical device leadership experience, with a strong track record of taking products from concept to commercial launch, and holds 10 issued U.S. patents. His expertise is expected to accelerate innovation and strengthen Nuwellis's ability to execute strategic initiatives in cardiorenal solutions.
Nuwellis Inc. announced strategic development initiatives to expand its Aquadex SmartFlow System into a broader extracorporeal therapy platform. The company aims to enhance the system's operating parameters to support higher blood flow rates, expanded pressure ranges, and broader compatibility with advanced extracorporeal therapies. This strategy is intended to extend Nuwellis' market beyond fluid overload into critical care applications like blood purification, immunomodulation, and extracorporeal life support.
Nuwellis, Inc. (Nasdaq: NUWE) announced its participation in four major medical conferences in October, focusing on pediatrics, critical care, and heart failure. The company aims to engage clinicians and raise awareness for its Aquadex SmartFlow® system, which provides precise fluid removal for patients suffering from fluid overload. These events are crucial for Nuwellis to advance its commercial strategy and strengthen relationships with specialists in its key growth markets.